On Monday, the Federal Trade Commission (FTC) launched an inquiry to understand exposure to false claims about “gender-affirming care,” with public comments due by Sept. 26. The FTC seeks to evaluate whether medical professionals may have violated Sections 5 and 12 of the FTC Act by failing to disclose material risks related to gender-affirming care.
Kaiser Permanente and Children’s National Hospital announced they will no longer provide gender transition-related medical interventions due to federal scrutiny of transgender care.
Download the Straight Arrow app today to get the stories that matter free from manipulation, bias or agenda.™
Point phone camera here
Children’s National Hospital also said it will discontinue prescribing gender-affirming medications, effective Aug. 30.
